CN114340635A - 5-甲基四氢叶酸的用途 - Google Patents
5-甲基四氢叶酸的用途 Download PDFInfo
- Publication number
- CN114340635A CN114340635A CN202080062025.8A CN202080062025A CN114340635A CN 114340635 A CN114340635 A CN 114340635A CN 202080062025 A CN202080062025 A CN 202080062025A CN 114340635 A CN114340635 A CN 114340635A
- Authority
- CN
- China
- Prior art keywords
- acid
- folic acid
- methyltetrahydrofolate
- use according
- congenital
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
5‑甲基四氢叶酸用于制备围孕期和/或妊娠期妇女预防新生儿先心病缺陷的药物或保健食品的用途。5‑甲基四氢叶酸具有预防先天性心脏病的作用，由有关5‑甲基四氢叶酸的预防用量可以超过1mg，与合成叶酸相比大剂量使用没有致畸作用，可以实现大剂量下预防出生缺陷，用于预防新生儿先天性心脏病。
Description
PCT国内申请，说明书已公开。
Claims (20)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910828557 | 2019-09-03 | ||
| CN2019108285577 | 2019-09-03 | ||
| PCT/CN2020/113157 WO2021043196A1 (zh) | 2019-09-03 | 2020-09-03 | 5-甲基四氢叶酸的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114340635A true CN114340635A (zh) | 2022-04-12 |
Family
ID=74853119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080062025.8A Pending CN114340635A (zh) | 2019-09-03 | 2020-09-03 | 5-甲基四氢叶酸的用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230043678A1 (zh) |
| EP (1) | EP4026548A4 (zh) |
| JP (1) | JP2022546834A (zh) |
| CN (1) | CN114340635A (zh) |
| WO (1) | WO2021043196A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023064399A1 (en) * | 2021-10-12 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Prenatal supplement |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066375A1 (en) * | 2011-11-05 | 2013-05-10 | South Alabama Medical Science Foundation | Methods, formulations, and kits for rapidly repleting folate levels in women |
| CN104116743A (zh) * | 2014-05-21 | 2014-10-29 | 烟台中洲制药有限公司 | 预防给药的叶酸药物组合物 |
| CN109939077A (zh) * | 2017-12-04 | 2019-06-28 | 深圳奥萨制药有限公司 | 一种含有5-甲基四氢叶酸的控释制剂 |
-
2020
- 2020-09-03 JP JP2022514615A patent/JP2022546834A/ja active Pending
- 2020-09-03 WO PCT/CN2020/113157 patent/WO2021043196A1/zh unknown
- 2020-09-03 US US17/639,993 patent/US20230043678A1/en active Pending
- 2020-09-03 EP EP20860261.5A patent/EP4026548A4/en active Pending
- 2020-09-03 CN CN202080062025.8A patent/CN114340635A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066375A1 (en) * | 2011-11-05 | 2013-05-10 | South Alabama Medical Science Foundation | Methods, formulations, and kits for rapidly repleting folate levels in women |
| CN104116743A (zh) * | 2014-05-21 | 2014-10-29 | 烟台中洲制药有限公司 | 预防给药的叶酸药物组合物 |
| CN109939077A (zh) * | 2017-12-04 | 2019-06-28 | 深圳奥萨制药有限公司 | 一种含有5-甲基四氢叶酸的控释制剂 |
Non-Patent Citations (1)
| Title |
|---|
| 石建等: "同型半胱氨酸、亚甲基四氢叶酸还原酶及叶酸与先天性心脏病的关系" * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022546834A (ja) | 2022-11-09 |
| US20230043678A1 (en) | 2023-02-09 |
| EP4026548A1 (en) | 2022-07-13 |
| EP4026548A4 (en) | 2023-09-06 |
| WO2021043196A1 (zh) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7423800B2 (ja) | ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用 | |
| CN105939728A (zh) | 用于治疗和预防肾病和脂肪肝病的方法 | |
| WO2017079463A1 (en) | Anti-aging compositions and methods for using same | |
| KR20220123224A (ko) | 로페콕시브의 신규 투여 형태 및 관련 방법 | |
| CN109890384A (zh) | 生物素镁组合物和使用方法 | |
| TWI719691B (zh) | 羅伊氏乳桿菌（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株ＧＫＲ１用於製備降低尿酸之組成物的用途 | |
| CN114209810B (zh) | 枸杞糖肽在制备用于预防或治疗炎性肠病的药物中的用途 | |
| CN114340635A (zh) | 5-甲基四氢叶酸的用途 | |
| CN103446166B (zh) | 肝功能改善剂 | |
| CN101642425A (zh) | 叶酸肠溶制剂组合物及其制备方法 | |
| CN109260182A (zh) | 大麻二酚在治疗肺动脉高压中的应用 | |
| CN103037901B (zh) | 抑制cd36以控制肥胖和胰岛素敏感性 | |
| EP2997969A1 (en) | Treatment agent and treatment method for intestinal examination or surgery | |
| JP7352275B2 (ja) | 更年期症状改善用組成物 | |
| CN105919096B (zh) | 一种保健食品组合物及其制剂和用途 | |
| JP2024506336A (ja) | 膠芽腫の治療方法 | |
| JP6090723B2 (ja) | 腎機能障害の予防又は改善剤 | |
| CN116036107A (zh) | 胡萝卜苷在制备预防或治疗心力衰竭药物中的应用 | |
| CN113413384A (zh) | 烟酸在制备治疗和/或预防肥胖女性生育障碍的药物中的应用 | |
| CN111214465A (zh) | 维拉帕米的抗衰老用途 | |
| CN113925866A (zh) | 激酶抑制剂在制备雄性避孕药品或者制品中的应用 | |
| CN114903985A (zh) | 一种组合物及其在防治高草酸尿症方面的应用 | |
| Lagarto et al. | Prenatal effects of natural calcium supplement on Wistar rats during organogenesis period of pregnancy | |
| Summers | Ethanol-related teratogenicity and neurobehavioural impairments: influence of dietary zinc supplementation during pregnancy. | |
| JP2019210239A (ja) | ８−ヒドロキシエイコサペンタエン酸の薬理用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |